 During the COVID-19 pandemic, we have seen some major changes in the management of multiple myeloma patients. And it's important to note that or to highlight that multiple myeloma patients are really considered as one vulnerable group to this infection. Therefore, the spirit of the management of these patients during the pandemic was about to protect them as much as possible. And this has to do, for instance, with the advice about social distancing to take some very strict measures when it comes to avoiding any risk of contamination. And this is why, for instance, we needed to minimize or to reduce the frequency when they come to the hospital. And this is why, for instance, whenever possible, we moved into applying oral therapy instead of IV or subcutaneous infusions. We moved into doing things at home whenever possible. When it comes, for instance, to infusions which are being performed twice per week, we try to reduce it into once weekly whenever possible. Another important change which is really crucial in the case of multiple myeloma is about the dosage and use of dexametazone. We know that this is a very potent immunosuppressive agent. And in a significant proportion of patients, we managed to reduce the dosage or even to discontinue the drug. I think the list of changes is extremely long, but I believe these were the main characteristics. In addition, for instance, to postponing any non-crucial or urgent intervention. And this has been the case, for instance, for autologous stem cell transplant in those patients who are eligible because we managed to deliver longer durations of induction in order to allow more time for the pandemic to calm down. So, yes, the COVID-19 pandemic had a significant impact on the management of multiple myeloma patients. And hopefully with these approaches, with these few changes, we managed to keep these patients at least the majority safe and well.